Tag:

AstraZeneca

Latest Headlines

Latest Headlines

AstraZeneca CEO jumps into asset-sale fray to 'focus on what we do well'

In announcing first-quarter earnings Thursday, AstraZeneca CEO Pascal Soriot sounded as if he'd been reading the deluge of trend stories analyzing pharma's latest spate of M&A. In fact, he's ready to participate, with a couple of sales/spinoffs together worth about $15 billion, according to analysts

AstraZeneca continues to chop back, spotlights immuno-oncology PhIII

AstraZeneca is continuing its campaign to refashion its image as it tries to shake off past setbacks and unsuccessful units and turn analysts' attention to its brightest pipeline prospects, particularly in cancer.

WuXi poaches an AstraZeneca exec to amp up Chinese R&D

Chinese CRO WuXi PharmaTech has convinced Steve Yang, head of Asian R&D for AstraZeneca, to jump ship, joining the company as it looks to expand its presence in its home country and abroad.

Bulk up or slim down? Maybe both: Pfizer said to weigh a $100B deal for AstraZeneca

We thought Pfizer was on a diet. After all, CEO Ian Read has garnered investor acclaim for his unit sales and spinoffs, and more of that action is expected. But the U.S.-based drug behemoth reportedly made a $100 billion-plus merger pitch to its struggling rival AstraZeneca. That would be quite a deal to digest.

Say what? Pfizer's $101B buyout pitch to AstraZeneca sparks a megadebate

Pfizer has reportedly made overtures offering to buy the struggling pharma giant AstraZeneca for $101 billion, setting the stage for what could be the first megamatchup in pharma land in years.

Pfizer, AstraZeneca back a new strategy for cancer drug R&D

A pair of pharma giants have partnered with a prominent cancer research charity in the U.K. on an innovative new approach to testing targeted oncology therapies, building on the country's national program for tumor testing in a way that may help make it a global center of cancer R&D.

GlaxoSmithKline joins a Big Pharma immuno-oncology R&D alliance

GlaxoSmithKline is taking a berth next to teams from AstraZeneca, Pfizer and Johnson & Johnson in an ambitious alliance of industry giants aimed at discovering some new products in the red-hot cancer R&D field.

Which brands grab the drug-spending title? AbbVie's Humira, AZ's Nexium lead the way

Which drugs cost U.S. health plans the most? Take a look at this year's iteration of Express Scripts' annual Drug Trend Report, and you'll find commentary on drug prices, the pharma industry, and American society. Not to mention a hint at which brands are best at getting themselves noticed.

AstraZeneca expands StarPharma deal for cancer drug delivery tech

AstraZeneca has expanded its deal with Australia's StarPharma, originally inked in September 2012, to use its drug delivery technology with a cancer drug in AstraZeneca's pipeline.

AstraZeneca cozies up to MRC scientists amid an R&D rethink

AstraZeneca isn't due to move into its new Cambridge, U.K., headquarters for another two years, but the British giant is already laying the groundwork for open collaboration in the biomedical hub, signing a deep-seated deal with the government-run Medical Research Council to work on drug discovery.